Active ingredientDihydroergotamineCat. No. P-D121-001CAS 511-12-6Family · Pharmaceutical analytical standards
Dihydroergotamine
A derivative of ergotamine synthesised in 1943 in Switzerland by Albert Hofmann and colleagues and approved in 1946: it is used for acute migraine attacks, as a nasal spray or by injection. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.
Did you know?It descends from ergotamine, the main alkaloid of the ergot fungus Claviceps purpurea, isolated in 1918 by Arthur Stoll; the prefix dihydro- means two extra hydrogen atoms in the molecule.
Go to the active ingredient →Active ingredientDihydroergotamineCat. No. P-D121-001CAS 511-12-6
Isotopically labelledDihydro Ergotamine-13C-d3 MesylateCat. No. P-D121-002CAS 1356841-81-0
Impurity9,10-Dihydroergotamine N-OxideCat. No. P-D121-003CAS 84094-90-6
ImpurityDihydroergotamine Impurity 1Cat. No. P-D121-004
Pharmacopoeial impurityDihydroergotamine EP Impurity CCat. No. P-D121-006CAS 2881077-62-7
Pharmacopoeial impurityDihydroergotamine EP Impurity ACat. No. P-D121-007CAS 113-15-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.